Core Viewpoint - The company has approved a stock incentive plan for 2025, granting 1.914 million restricted stocks and 3.9678 million stock options to 405 incentive targets, aimed at enhancing employee motivation and aligning their interests with shareholders [2][19][24]. Summary by Sections Incentive Plan Overview - The incentive plan includes the grant of 1.914 million restricted stocks at a price of 15.93 CNY per share and 3.9678 million stock options at an exercise price of 31.86 CNY per option [2][3][21]. Grant Conditions - The grant date for the restricted stocks and stock options is set for October 16, 2025, with a total of 405 incentive targets, including directors, senior management, and key technical personnel [2][3][12]. Performance Assessment Requirements - The performance assessment for the incentive plan will cover the fiscal years 2025 to 2028, with specific annual performance targets established for each year [6][29]. Decision-Making Process - The decision-making process for the incentive plan involved multiple board meetings and approvals, culminating in a shareholder meeting on September 23, 2025, where the plan was ratified [9][10][12]. Compliance and Legal Review - The company has conducted a self-examination regarding insider trading and confirmed that no violations occurred prior to the public disclosure of the incentive plan [10][25]. Financial Impact - The estimated financial impact of the incentive plan on the company's net profit is expected to be minimal, with potential positive effects on operational efficiency and management motivation [30][31]. Legal Opinions - Legal opinions confirm that the incentive plan complies with relevant laws and regulations, and the granting conditions have been met [32][33].

Group 1 - Hubei Jiuyuan Biomedical Technology Co., Ltd. has been established with a registered capital of 30 million yuan [1] - The legal representative of the company is Lü Xiaowan [1] - The business scope includes sales of Class I medical devices, sales of pre-packaged health food, general equipment repair, specialized equipment repair, and non-residential real estate leasing [1] Group 2 - The company is wholly owned by Jiuzhoutong Medical Device Group Co., Ltd., a subsidiary of Jiuzhoutong (600998) [1]

Group 1 - The company held its 10th meeting of the 4th Board of Directors on August 29, 2025, with all 7 directors present, meeting the legal requirements [1][2] - The Board approved the draft of the 2025 Employee Stock Ownership Plan (ESOP) to enhance talent retention and align employee interests with shareholder value [2][3] - The voting result for the ESOP was unanimous, with 6 votes in favor and no opposition, representing 100% of the votes cast [3][4] Group 2 - The company plans to implement a 2025 Restricted Stock and Stock Option Incentive Plan to attract and retain talent while ensuring alignment of interests among shareholders, the company, and employees [5][6] - The voting result for the incentive plan was also unanimous, with 6 votes in favor and no opposition, representing 100% of the votes cast [6][7] - The Board proposed to authorize the shareholders' meeting to grant the Board the authority to manage the implementation of the incentive plan, including adjustments based on policy changes [7][8] Group 3 - The company will submit the ESOP and the incentive plan for approval at the upcoming shareholders' meeting [3][4] - The Board will also seek authorization to handle necessary administrative tasks related to the incentive plan, including approvals and registrations with relevant authorities [8][9] - The company aims to ensure the effective implementation of both plans to support its long-term development strategy [5][6]

Company Performance - As of August 12, 2025, the stock price of Kailing Medical (300633) closed at 34.53 yuan, an increase of 1.59% with a turnover rate of 1.99% and a trading volume of 86,300 lots, amounting to 300 million yuan [1] - The latest quarterly report shows total operating revenue of 430 million yuan, a year-on-year decrease of 10.29%, and a net profit attributable to shareholders of 8.07 million yuan, down 91.94% year-on-year [1] - The company's non-recurring net profit was 5.99 million yuan, a decrease of 93.49% year-on-year, with a current ratio of 3.527, quick ratio of 2.514, and a debt-to-asset ratio of 21.81% [1] Capital Flow - On the day of reporting, the main capital saw a net outflow of 12.41 million yuan, accounting for 4.14% of the total transaction amount [1] - Large orders experienced a net outflow of 19.99 million yuan, representing 6.67% of the transaction amount, while small orders had a net inflow of 27.30 million yuan, making up 9.11% of the transaction amount [1] Company Background - Kailing Medical, officially known as Shenzhen Kailing Biomedical Technology Co., Ltd., was established in 2002 and is located in Shenzhen, primarily engaged in technology promotion and application services [2] - The company has a registered capital of 4.327 billion yuan and a paid-in capital of 2.516 billion yuan, with Chen Zhiqiang as the legal representative [1][2] - The company has made investments in 12 enterprises, participated in 2,045 bidding projects, and holds 249 trademark registrations and 1,580 patents, along with 269 administrative licenses [2]